Malignant neoplasm of craniopharyngeal duct
ICD-10 C75.2 is a billable code used to indicate a diagnosis of malignant neoplasm of craniopharyngeal duct.
C75.2 refers to a malignant neoplasm originating from the craniopharyngeal duct, which is a remnant of the embryonic development of the pituitary gland. This type of tumor is classified as an endocrine malignancy and can disrupt normal hormone production and regulation. The craniopharyngeal duct is located in the midline of the brain, and tumors in this area can lead to various endocrine dysfunctions due to their proximity to the pituitary gland and hypothalamus. Symptoms may include headaches, visual disturbances, and signs of hormonal imbalance such as growth retardation in children or hyperprolactinemia. Diagnosis typically involves imaging studies such as MRI or CT scans, followed by histopathological examination to confirm malignancy. Treatment options may include surgical resection, radiation therapy, and hormone replacement therapy, depending on the extent of the disease and the patient's overall health. Given the complex interplay between the tumor and the endocrine system, careful monitoring of hormone levels is essential during and after treatment.
Thorough documentation of hormone levels, symptoms, and treatment responses.
Management of hormonal imbalances post-tumor treatment.
Endocrinologists must monitor for long-term endocrine dysfunctions.
Detailed operative reports and post-operative follow-up notes.
Surgical resection of the tumor and management of complications.
Neurosurgeons must document the extent of resection and any complications affecting endocrine function.
Used during surgical intervention for C75.2.
Operative report detailing the extent of resection.
Neurosurgeons must document any complications affecting endocrine function.
Common symptoms include headaches, visual disturbances, and signs of hormonal imbalances such as growth retardation or hyperprolactinemia.
Diagnosis typically involves imaging studies like MRI or CT scans, followed by histopathological examination to confirm malignancy.
Treatment may include surgical resection, radiation therapy, and hormone replacement therapy, depending on the extent of the disease.
